Your session is about to expire
← Back to Search
Mitochondrial Targeted Antioxidant
Mitoquinone for Long-COVID
N/A
Recruiting
Led By Joel Douglas Trinity, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
50 years of age or greater
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.
Awards & highlights
Study Summary
This trial will focus on improving the health of older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to improve vascular endothelial function.
Who is the study for?
This trial is for veterans and others aged 50 or older who are recovering from COVID-19, specifically those with Long-COVID symptoms 3-12 months after diagnosis. Participants must be able to consent and have a confirmed SARS-CoV-2 test at the time of their initial illness. People with severe heart disease, uncontrolled high blood pressure, extreme obesity, recent smokers, or certain chronic diseases cannot join.Check my eligibility
What is being tested?
The study tests Mitoquinone (a supplement aimed at reducing oxidative stress) against a placebo in improving vascular function post-COVID. It aims to develop therapies that help rehabilitation by addressing long-term effects of COVID on the body's blood vessels.See study design
What are the potential side effects?
While specific side effects are not listed here, Mitoquinone may cause similar reactions as other supplements targeting oxidative stress such as digestive discomfort or allergic reactions; placebos typically have no active ingredients but can lead to perceived side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 50 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, months 3 and 6, and every 6 months thereafter until the end of year 4.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Respiration
Change in Flow Mediated Dilation (FMD)
Leg
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Exercise RehabilitationExperimental Treatment2 Interventions
Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10).
Group II: Exercise Rehabilitation with PlaceboPlacebo Group2 Interventions
Participants will be assigned to Exercise+Placebo rehabilitation using block randomization (block size 10)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,620 Previous Clinical Trials
3,316,042 Total Patients Enrolled
Joel Douglas Trinity, PhDPrincipal InvestigatorVA Salt Lake City Health Care System, Salt Lake City, UT
1 Previous Clinical Trials
75 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a current smoker or quit smoking within the last 10 years.I am not taking Mito-Q and am willing to stop any supplements.My heart condition has been unstable or severe in the last 6 months.I have severe COPD.I have physical limitations that prevent me from exercising.My blood pressure is not higher than 160/100 mmHg.I have been diagnosed with Alzheimer's disease.You weigh more than 100 pounds for every 5 feet of your height.I have had a stroke in the past year.My kidneys are not working well (creatinine clearance <30).I have severe blockage in my leg arteries.I am on dialysis for chronic kidney disease.You have a condition that affects your memory and thinking.I am 50 years old or older.If you had COVID-19, we need a positive test result from around the time you were diagnosed.I had COVID-19 between 3 to 12 months ago.
Research Study Groups:
This trial has the following groups:- Group 1: Exercise Rehabilitation
- Group 2: Exercise Rehabilitation with Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the upper limit of individuals participating in this clinical experiment?
"Affirmative. According to the information hosted on clinicaltrials.gov, this study is currently searching for volunteers with a deadline of November 23rd 2022. 300 participants are needed at one site in order to complete enrollment."
Answered by AI
Are there any open spots in this trial for participants?
"According to clinicaltrials.gov, the research team is still recruiting participants for this study; it was initially listed on November 1st 2022 and underwent its last update on November 23rd 2022."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger